Abstracts
The human microbiome has been suggested to be involved in the regulation of response to anticancer therapies. However, little is known regarding changes of commensal microbes in cancer patients during radiotherapy and whether these changes are associated with response to treatment. We conducted a prospective, longitudinal cohort with sixty-two newly diagnosed nasopharyngeal carcinoma (NPC) patients who were scheduled for radiotherapy-based treatment. Nasopharyngeal swabs were collected longitudinally before radiotherapy, during radiotherapy, and after radiotherapy. The nasopharyngeal microbiome was assessed using 16S rRNA amplicon sequencing. All patients were followed up to 24 months to define an early or late clinical response. We demonstrated the beta-diversity of the nasopharyngeal microbiome showed temporal changes throughout treatment. The magnitude of changes was stably and significantly different between the early and late responders. The temporal microbial networks among NPC patients with early response differed significantly from those with late response. Seven amplicon sequence variants (ASVs) mapped to Corynebacterium were lost during treatment. Twenty-eight abundant ASVs differed by patients’ responses throughout treatment. Among them, 10 ASVs differed between the early responders and late responders before getting any treatment and the difference was consistent along the radiotherapy course. This study addressed the temporal changes of the nasopharyngeal microbiome in NPC patients during radiotherapy and suggested a significant association with clinical response. The subject-specific changes of the nasopharyngeal microbiome might serve as a potential predictor for clinical response to radiotherapy.
Importance The human microbiome has been suggested to be involved in the regulation of response to anticancer therapies. However, little is known regarding changes of commensal microbes in cancer patients during radiotherapy and whether these changes have an impact on response to treatment. In this longitudinal study of nasopharyngeal carcinoma patients, we demonstrate that the temporal changes of the nasopharyngeal microbiome in NPC patients during radiotherapy-based treatment and suggest a significant association with patients’ clinical response. We identify 28 abundant amplicon sequence variants differed significantly between the early and late responders throughout treatment. Among them, 10 are consistently differed by patients’ responses. These subject-specific changes might serve as a potential predictor for clinical response to radiotherapy. To the best of our knowledge, this is the first example that the commensal microbiome may influence the response to radiotherapy-based treatment in cancer patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge funding from the Swedish Cancer Society (2016/510 to W. Ye) and the Swedish Research Council (2015-02625, 2015-06268, 2017-05814 to W. Ye); the National Natural Science Foundation of China (81360405 to R. Wang) and the Guangxi (China) Science and Technology Program Project (GK AD17129013 to R. Wang); the Natural Science Foundation of Guangxi Medical University for Junior Scientists (GXMUYSF201203 to T. Huang). T. Huang was also partly supported by a grant from the China Scholarship Council (201408450018).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw sequencing data and metadata are deposited in ENA under accession XXXXX. More details can be achieved by contacting the corresponding authors.
